News
SPRB
0.7059
-0.04%
-0.0003
Weekly Report: what happened at SPRB last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at SPRB last week (0401-0405)?
Weekly Report · 04/08 09:19
Weekly Report: what happened at SPRB last week (0325-0329)?
Weekly Report · 04/01 09:19
Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know
NASDAQ · 03/27 16:00
Weekly Report: what happened at SPRB last week (0318-0322)?
Weekly Report · 03/25 09:19
Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why
NASDAQ · 03/21 14:20
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spruce Biosciences, Inc. Investors who purchased Spruce securities are encouraged to assist the investigation. On March 13, 2024, Spruce's stock price plunged 75% after a failed study for a drug candidate.
Barchart · 03/21 09:00
Spruce Biosciences’ Compliance Hurdle: Navigating Sarbanes-Oxley to Protect Market Value
TipRanks · 03/20 06:02
Weekly Report: what happened at SPRB last week (0311-0315)?
Weekly Report · 03/18 09:19
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and Spruce Biosciences (SPRB)
2 analysts have maintained Buy ratings on Terns Pharmaceuticals and Spruce Biosciences. JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on the Healthcare sector stock today. The company’s shares closed at $7.20 today.
TipRanks · 03/18 04:30
Spruce Biosciences' Hormone Treatment Stumbles In Trials, Prompts Stock Freefall
Spruce Biosciences Inc (NASDAQ:SPRB) shares plummeted on Thursday. The company released topline results from its CAHmelia-203 Phase 2b study of tildacerfont in adult classic congenital adrenal hyperplasia (CAH) The company's drug did not achieve the primary efficacy endpoint.
Benzinga · 03/14 20:15
Dow Dips Over 100 Points; Dick's Sporting Goods Earnings Top Views
U.S. Stocks traded lower toward the end of trading on Thursday. The Dow Jones index fell more than 100 points. Energy shares jumped by 0.8% as real estate shares fell by 2.4%. Dick's Sporting Goods reported better-than-expected fourth-quarter results and issued strong guidance.
Benzinga · 03/14 18:46
Spruce Biosciences Touches 52-Week Low After Unfavorable Genetic Disease Study Results
Spruce Biosciences touched a 52-week low Thursday following unfavorable clinical trial results and job cuts. The stock was recently down 81% to 97 cents. Spruce's results could help Neurocrine's crinecerfont, analysts say. The company's shares were recently down 2.5%.
Dow Jones · 03/14 18:31
BUZZ-U.S. STOCKS ON THE MOVE-G-III Apparel Group, Tesla, MicroStrategy
G-III Apparel Group, Tesla, MicroStrategy and United States Steel fall on Thursday. The Dow Jones Industrial Average was down 0.48% and the S&P 500 and Nasdaq Composite also fell. Wall Street's main indexes slipped on Thursday after hotter-than-expected producer prices data.
Reuters · 03/14 18:02
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Limbach Holdings, Inc. Fell 14.7% to $42.42 on Thursday. The company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates. Aptorum Group Limited and Presto Automation were among the stocks moving in today's mid-day session. Build-A-Bear Workshop and DICK'S Sporting Goods were also among the gainers.
Benzinga · 03/14 17:38
12 Health Care Stocks Moving In Thursday's Intraday Session
Psyence Biomedical (NASDAQ:PBM) shares rose 52.9% to $1.59 during Thursday's regular session. Aptorum Gr stock moved upwards by 43.65% to $6.22. Mira Pharmaceuticals stock rose by 17.27%.
Benzinga · 03/14 17:31
Crude Oil Moves Higher; Dollar General Posts Upbeat Earnings
The Dow Jones index fell more than 100 points on Thursday. U.S. Stocks traded lower midway through trading. Energy shares jumped by 0.4% on Thursday after Dollar General Corp. Posted better-than-expected earnings for fourth quarter. Asian markets closed mixed in Asia Pacific markets.
Benzinga · 03/14 16:14
BUZZ-U.S. STOCKS ON THE MOVE-Robinhood Markets, ADM, Vaalco Energy
Dow Jones Industrial Average down 0.25%, S&P 500 and Nasdaq Composite also down. Producer prices data comes in hotter than expected. Build-A-Bear Workshop, ADM and Under Armour rise after strong quarterly results. Robinhood Markets, Netflix and GIII Apparel all rise.
Reuters · 03/14 16:13
Spruce Biosciences Price Target Cut to $2.00/Share From $9.00 by RBC Capital
Dow Jones · 03/14 15:16
Spruce Biosciences Cut to Sector Perform From Outperform by RBC Capital
Dow Jones · 03/14 15:16
More
Webull provides a variety of real-time SPRB stock news. You can receive the latest news about Spruce Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SPRB
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders with significant unmet medical needs. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). It is also developing Tildacerfont for females suffering from polycystic ovary syndrome (PCOS). It has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with elevated levels of androstenedione (A4) at baseline. It has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 at baseline focused on glucocorticoid reduction. The Company also investigates tildacerfont for the treatment of classic CAH in children.